MDxHealth’s (MDXH) Neutral Rating Reiterated at BTIG Research

BTIG Research restated their neutral rating on shares of MDxHealth (NASDAQ:MDXH) in a report released on Monday, MarketBeat.com reports.

Several other equities analysts have also recently weighed in on the company. Weiss Ratings cut MDxHealth from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. Lake Street Capital lowered MDxHealth from a “buy” rating to a “hold” rating and set a $0.50 target price on the stock. in a report on Friday, October 16th. Wall Street Zen raised MDxHealth to a “sell” rating in a report on Saturday, August 15th. Finally, Craig Hallum downgraded MDxHealth from a “buy” rating to a “hold” rating in a research report on Friday, October 16th. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $1.33.

MDxHealth Trading Up 10.5%

NASDAQ:MDXH opened at $0.21 on Monday. MDxHealth has a 1 year low of $0.17 and a 1 year high of $5.33. The firm’s fifty day simple moving average is $0.63 and its 200 day simple moving average is $0.87. The firm has a market capitalization of $10.63 million, a PE ratio of -0.30 and a beta of 1.68.

MDxHealth (NASDAQ:MDXH) last released its earnings results on Friday, August 14th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. The firm had revenue of $27.21 million for the quarter, compared to analyst estimates of $26.14 million. As a group, analysts anticipate that MDxHealth will post -0.49 EPS for the current fiscal year.

Hedge Funds Weigh In On MDxHealth

Large investors have recently added to or reduced their stakes in the company. Squarepoint Ops LLC acquired a new stake in shares of MDxHealth during the 2nd quarter worth approximately $82,000. Bank of America Corp DE increased its position in shares of MDxHealth by 213.9% during the first quarter. Bank of America Corp DE now owns 43,492 shares of the company’s stock valued at $100,000 after purchasing an additional 29,638 shares during the period. Renaissance Technologies LLC increased its position in shares of MDxHealth by 21.8% during the first quarter. Renaissance Technologies LLC now owns 304,700 shares of the company’s stock valued at $701,000 after purchasing an additional 54,600 shares during the period. Finally, Perkins Capital Management Inc. increased its position in shares of MDxHealth by 7.1% during the first quarter. Perkins Capital Management Inc. now owns 1,476,441 shares of the company’s stock valued at $3,396,000 after purchasing an additional 97,500 shares during the period.

MDxHealth Company Profile

MDxHealth is a precision diagnostics company focused on improving the detection, diagnosis and management of cancer. The company develops and commercializes molecular and genomic tests designed to help physicians assess cancer risk, guide treatment decisions and monitor patients, with a primary focus on urological cancers.

Its product portfolio includes ConfirmMDx, a tissue-based test intended to help identify men who may have clinically significant prostate cancer after a prior negative biopsy; SelectMDx, a urine-based test that helps assess the likelihood of clinically significant prostate cancer; and ResolveMDx, a molecular test designed to support prostate cancer risk assessment.